Ruxolitinib for the treatment of primary myelofibrosis

American Journal of Health-System Pharmacy

Volumn 71, Issue 6, 2014, Pages 453-462

  Swaim, Starla J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOCHROME P450 3A4; JANUS KINASE 1; JANUS KINASE 2; PLACEBO; RUXOLITINIB; JANUS KINASE; PYRAZOLE DERIVATIVE;

ANEMIA; AREA UNDER THE CURVE; BLEEDING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; HEADACHE; HIGH RISK PATIENT; HUMAN; MAXIMUM PLASMA CONCENTRATION; MOLECULARLY TARGETED THERAPY; MYELOID METAPLASIA; NEUTROPENIA; OVERALL SURVIVAL; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; PRURITUS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SPLEEN SIZE; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ANIMAL; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; TREATMENT OUTCOME;

ANEMIA; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; JANUS KINASES; PRIMARY MYELOFIBROSIS; PYRAZOLES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84904286100     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120602     Document Type: Review

References (31)

1. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med. 2009; 60:233-45.
2. Rollison DE, Howlander N, Smith MT et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008; 112:45-52.
3. Visani G, Finelli C, Castelli U et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990; 75:4-9.
4. Cervantes F, Dupriez B, Pereira A et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009; 113:2895-901.
5. Passamonti F, Cervantes F, Vannucchi AM et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010; 115:1703-8.
6. Gangat N, Caramazza D, Vaidya R et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011; 29:392-7.
7. Tefferi A, Viadya R, Caramazza D et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011; 29:1356-63.
8. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2010; 342:1255-65.
9. Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2011; 86:1018-26.
10. Cervantes F, Alvarez- Larrán A, Hernández-Boluda JC et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol. 2004; 127:399-403.
11. Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC et al. Darbepoietin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol. 2006; 134:184-6.
12. Cervantes F, Martinez-Trillos A. Myelofibrosis: an update on curent pharmacotherapy and future directions. Expert Opin Pharmacother. 2013; 14:873-84.
13. Tefferi A. How I treat myelofibrosis. Blood. 2011; 117:3494-504.
14. Siragusa S, Vaidya R, Tefferi A. Hydroxyurea effect on marked splenomegaly associated with primary myelofibrosis: response rates and correlation with JAK2V617F allele burden. Blood. 2009; 114:abstract 4971.
15. Mesa RA, Nagorney DS, Schwager S et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006; 107:361-70.
16. Tefferi A, Mesa RA, Nagorney DM et al. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000; 95:2226-33.
17. Elliott MA, Tefferi A. Splenic irradiation in the melofibrosis with myeloid metaplasia: a review. Blood Rev. 1999; 13:163-70.
18. Geyer HL, Tibes R, Mesa RA. JAK2 inhibitors and their impact in myeloproliferative neoplasms. Hematology. 2012; 17(suppl):S129-32.
19. Jakafi (ruxolitinib) package insert. Wilmington, DE: Incyte Coporation; 2011 Nov.
20. Pesu M, Laurence A, Kishore N et al. Therapeutic targeting of Janus kinases. Immunol Rev. 2008; 223:132-42.
21. Shi JG, Chen X, McGee RF et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011; 51:1644-54.
22. Shilling AD, Nedza FM, Emm T et al. Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos. 2010; 38:2023-31.
23. Shi JG, Chen X, Emm T et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol. 2012; 52:809-18.
24. Verstovsek S, Kantarjian H, Mesa RA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010; 363:1117-27.
25. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011; 365:1455-7.
26. Verstovsek S, Kantarjian HM, Estrov Z et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012; 120:1202-9.
27. Tefferi A, Barosi G, Mesa RA et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006; 108:1497-503.
28. Verstovsek S, Mesa RA, Gotlib J et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366:799-807.
29. Harrison C, Kiladjian JJ, Al-Ali HK et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366:787-98.
30. Incyte Corporation. IncyteCARES: support for patients with myelofibrosis. www.jakafi.com/IncyteCARES (accessed 2013 Dec 16).
31. Red book online (Internet database). Greenwood Village, CO: Thomson Healthcare. Updated periodically.